In our work to develop small-molecule preclinical drug candidates that can contribute to new cancer therapies, speed and precision are crucial. Through our collaboration with SciLifeLab's Drug Discovery and Development (DDD) Platform, we have access to advanced protein quality analysis - a key component of our fragment-based drug development. This infrastructure allows us to act quickly, avoid bottlenecks and focus on what we do best. Read more about how the collaboration helps shorten the path from idea to drug candidate at SciLifeLab website.